Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A
Wolfgang Miesbach/LinkedIn,Jerzy Windyga/mzdrowie.pl
Jul 29, 2026, 10:20

Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:

”FRONTIER4 — denecimig (Mim8) long-term data presented at ISTH 2026 in Paris.

Among the clinically relevant prophylaxis updates, OC 02.4 by Jerzy Windyga reported interim safety and efficacy results from FRONTIER4, the long-term extension study of the denecimig (Mim8) programme in haemophilia A.

Denecimig is a next-generation subcutaneous FVIIIa mimetic, optimised for FIXa cofactor activity and thrombin generation.

What sets the programme apart is the dosing flexibility: once weekly, once every two weeks, or once monthly — by patient choice after week 26.

Interim analysis in adults and adolescents (≥12 years, N=365; median observation ~0.5 years):

Efficacy

  • Overall estimated mean ABR 0.75, consistently low across all three schedules (QW 0.91, Q2W 0.55, QM 0.74)
  • Median observed ABR was zero in every subgroup
  • 71.2% with zero treated bleeds
  • Low spontaneous bleeds (ABR 0.09) and near-absent target-joint bleeds (ABR 0.01, 97% zero)
  • Low ABRs irrespective of FVIII inhibitor status (positive 0.15, negative 0.88)

Safety

  • No thromboembolic events
  • Injection-site reactions in 1.8% of injections (108/6138); the majority of AEs mild
  • No clinical evidence of neutralising anti-denecimig antibodies

Monthly dosing maintained bleed protection comparable to weekly — a genuine opportunity to reduce treatment burden, with low bleed rates holding regardless of inhibitor status.

Congratulations to the investigators and, above all, to the FRONTIER4 participants.”

Wolfgang Miesbach: FRONTIER4 Long-Term Results Highlight the Promise of Denecimig in Haemophilia A

Stay updated with Hemostasis Today.

bleeding disorders Denecimig FRONTIER4 haemophilia Health Hematology Hemostasis Hemostasis News Hemostasis Today ISTH 2026 Jerzy Windyga Medicine Mim8 Wolfgang Miesbach
NewsFeed